

1 TO THE HONORABLE SENATE:

2 The Committee on Health and Welfare to which was referred House Bill  
3 No. 353 entitled “An act relating to pharmacy benefit management”  
4 respectfully reports that it has considered the same and recommends that the  
5 Senate propose to the House that the bill be amended by striking out all after  
6 the enacting clause and inserting in lieu thereof the following:

7 Sec. 1. INTENT

8 It is the intent of the General Assembly to increase access to needed  
9 medications by making prescription drugs more affordable and accessible to  
10 Vermonters by increasing State regulation of pharmacy benefit managers and  
11 pharmacy benefit management. It is also the intent of the General Assembly to  
12 stabilize and safeguard against the loss of more independent and community  
13 pharmacies, where pharmacists provide personalized care to Vermonters and  
14 help them with their health care needs, including medication management,  
15 medication adherence, and health screenings.

16 Sec. 1a. 18 V.S.A. § 9421 is amended to read:

17 § 9421. PHARMACY BENEFIT MANAGEMENT; REGISTRATION;

18 INSURER AUDIT OF PHARMACY BENEFIT MANAGER

19 ACTIVITIES

20 \* \* \*





1 insurance policy or subscriber contract or plan and in compliance with all  
2 applicable provisions of Title 8 and this title.

3 (b) A pharmacy benefit manager shall provide notice to the health insurer  
4 that the terms contained in subsection (c) of this section may be included in the  
5 contract between the pharmacy benefit manager and the health insurer.

6 (c) A pharmacy benefit manager that provides pharmacy benefit  
7 management for a health plan shall do all of the following:

8 (1) Provide all financial and utilization information requested by a  
9 health insurer relating to the provision of benefits to beneficiaries through that  
10 health insurer's health plan and all financial and utilization information  
11 relating to services to that health insurer. A pharmacy benefit manager  
12 providing information under this subsection may designate that material as  
13 confidential. Information designated as confidential by a pharmacy benefit  
14 manager and provided to a health insurer under this subsection ~~may~~ shall not  
15 be disclosed by the health insurer to any person without the consent of the  
16 pharmacy benefit manager, except that disclosure may be made by the health  
17 insurer:

18 (A) in a court filing under the consumer protection provisions of  
19 9 V.S.A. chapter 63, provided that the information shall be filed under seal and  
20 that prior to the information being unsealed, the court shall give notice and an

1 opportunity to be heard to the pharmacy benefit manager on why the  
2 information should remain confidential;

3 (B) to State and federal government officials;

4 (C) when authorized by 9 V.S.A. chapter 63;

5 ~~(C)~~(D) when ordered by a court for good cause shown; or

6 ~~(D)~~(E) when ordered by the Commissioner as to a health insurer as  
7 defined in subdivision 9471(2)(A) of this title pursuant to the provisions of  
8 Title 8 and this title.

9 (2) Notify a health insurer in writing of any proposed or ongoing  
10 activity, policy, or practice of the pharmacy benefit manager that presents,  
11 directly or indirectly, any conflict of interest with the requirements of this  
12 section.

13 (3) With regard to the dispensation of a substitute prescription drug for a  
14 prescribed drug to a beneficiary in which the substitute drug costs more than  
15 the prescribed drug and the pharmacy benefit manager receives a benefit or  
16 payment directly or indirectly, disclose to the health insurer the cost of both  
17 drugs and the benefit or payment directly or indirectly accruing to the  
18 pharmacy benefit manager as a result of the substitution.

19 (4) ~~Unless the contract provides otherwise, if~~ If the pharmacy benefit  
20 manager derives any payment or benefit for the dispensation of prescription  
21 drugs within the State based on volume of sales for certain prescription drugs

1 or classes or brands of drugs within the State, pass that payment or benefit on  
2 in full to the health insurer.

3 (5) Disclose to the health insurer all financial terms and arrangements  
4 for remuneration of any kind that apply between the pharmacy benefit manager  
5 and any prescription drug manufacturer that relate to benefits provided to  
6 beneficiaries under or services to the health insurer's health plan, including  
7 formulary management and drug-switch programs, educational support, claims  
8 processing, and pharmacy network fees charged from retail pharmacies and  
9 data sales fees. A pharmacy benefit manager providing information under this  
10 subsection may designate that material as confidential. Information designated  
11 as confidential by a pharmacy benefit manager and provided to a health insurer  
12 under this subsection ~~may~~ shall not be disclosed by the health insurer to any  
13 person without the consent of the pharmacy benefit manager, except that  
14 disclosure may be made by the health insurer:

15 (A) in a court filing under the consumer protection provisions of  
16 9 V.S.A. chapter 63, provided that the information shall be filed under seal and  
17 that prior to the information being unsealed, the court shall give notice and an  
18 opportunity to be heard to the pharmacy benefit manager on why the  
19 information should remain confidential;

20 (B) when authorized by 9 V.S.A. chapter 63;

21 (C) when ordered by a court for good cause shown; or

1 (D) when ordered by the Commissioner as to a health insurer as  
2 defined in subdivision 9471(2)(A) of this title pursuant to the provisions of  
3 Title 8 and this title.

4 (d) At least annually, a pharmacy benefit manager that provides pharmacy  
5 benefit management for a health plan shall disclose to the health insurer, the  
6 Department of Financial Regulation, and the Green Mountain Care Board the  
7 aggregate amount the pharmacy benefit manager retained on all claims charged  
8 to the health insurer for prescriptions filled during the preceding calendar year  
9 in excess of the amount the pharmacy benefit manager reimbursed pharmacies.

10 (e) A pharmacy benefit manager contract with a health insurer shall not  
11 contain any provision purporting to reserve discretion to the pharmacy benefit  
12 manager to move a drug to a higher tier or remove a drug from its drug  
13 formulary any more frequently than two times per year.

14 (f)(1) A pharmacy benefit manager shall not require a covered person  
15 purchasing a covered prescription drug to pay an amount greater than the lesser  
16 of:

17 (A) the cost-sharing amount under the terms of the health benefit

18 plan;

19 (B) the maximum allowable cost for the drug; or

1           (C) the amount the covered person would pay for the drug, after  
2           application of any known discounts, if the covered person were paying the cash  
3           price.

4           (2) Any amount paid by a covered person under subdivision (1) of this  
5           subsection shall be attributed toward any deductible and, to the extent  
6           consistent with Sec. 2707 of the Public Health Service Act (42 U.S.C.  
7           § 300gg-6), the annual out-of-pocket maximums under the covered person’s  
8           health benefit plan.

9           (g) Compliance with the requirements of this section is required for  
10          pharmacy benefit managers entering into contracts with a health insurer in this  
11          State for pharmacy benefit management in this State.

12          § 9473. PHARMACY BENEFIT MANAGERS; REQUIRED PRACTICES  
13                          WITH RESPECT TO PHARMACIES

14          (a) Within 14 calendar days following receipt of a pharmacy claim, a  
15          pharmacy benefit manager or other entity paying pharmacy claims shall do one  
16          of the following:

17                  (1) Pay or reimburse the claim.

18                  (2) Notify the pharmacy in writing that the claim is contested or denied.

19          The notice shall include specific reasons supporting the contest or denial and a  
20          description of any additional information required for the pharmacy benefit  
21          manager or other payer to determine liability for the claim.



1           (b) A participation contract between a pharmacy benefit manager and a  
2           pharmacist shall not prohibit, restrict, or penalize a pharmacy or pharmacist in  
3           any way from disclosing to any covered person any health care information  
4           that the pharmacy or pharmacist deems appropriate, including:

5                     (1) the nature of treatment, risks, or alternatives to treatment;

6                     (2) the availability of alternate therapies, consultations, or tests;

7                     (3) the decision of utilization reviewers or similar persons to authorize  
8           or deny services;

9                     (4) the process that is used to authorize or deny health care services; or

10                    (5) information on finance incentives and structures used by the health  
11           insurer.

12           (c) A pharmacy benefit manager or other entity paying pharmacy claims  
13           shall not:

14                    (1) ~~impose a higher co-payment for a prescription drug than the co-~~  
15           ~~payment applicable to the type of drug purchased under the insured's health~~  
16           ~~plan;~~

17                    (2) ~~impose a higher co-payment for a prescription drug than the~~  
18           ~~maximum allowable cost for the drug;~~

19                    (3) ~~require a pharmacy to pass through any portion of the insured's co-~~  
20           ~~payment, or patient responsibility, to the pharmacy benefit manager or other~~  
21           payer;

1           (2) prohibit a pharmacy or pharmacist from discussing information  
2           regarding the total cost for pharmacist services for a prescription drug;

3           ~~(4)~~(3) prohibit or penalize a pharmacy or pharmacist for providing  
4           information to an insured regarding the insured’s cost-sharing amount for a  
5           prescription drug; or

6           ~~(5)~~(4) prohibit or penalize a pharmacy or pharmacist for the pharmacist  
7           or other pharmacy employee disclosing to an insured the cash price for a  
8           prescription drug or selling a lower cost drug to the insured if one is available.

9           (d) A pharmacy benefit manager contract with a participating pharmacist or  
10          pharmacy shall not prohibit, restrict, or limit disclosure of information to the  
11          Commissioner, law enforcement, or State and federal government officials,  
12          provided that:

13           (1) the recipient of the information represents that the recipient has the  
14           authority, to the extent provided by State or federal law, to maintain  
15           proprietary information as confidential; and

16           (2) prior to disclosure of information designated as confidential, the  
17           pharmacist or pharmacy:

18           (A) marks as confidential any document in which the information  
19           appears; and

20           (B) requests confidential treatment for any oral communication of the  
21           information.

1        (e) A pharmacy benefit manager shall not terminate a contract with or  
2        penalize a pharmacist or pharmacy due to the pharmacist or pharmacy:

3            (1) disclosing information about pharmacy benefit manager practices,  
4        except for information determined to be a trade secret under State law or by the  
5        Commissioner, when disclosed in a manner other than in accordance with  
6        subsection (d) of this section; or

7            (2) sharing any portion of the pharmacy benefit manager contract with  
8        the Commissioner pursuant to a complaint or query regarding the contract's  
9        compliance with the provisions of this chapter.

10        ~~(e)~~(f) For each drug for which a pharmacy benefit manager establishes a  
11        maximum allowable cost in order to determine the reimbursement rate, the  
12        pharmacy benefit manager shall do all of the following:

13            (1) Make available, in a format that is readily accessible and  
14        understandable by a pharmacist, the actual maximum allowable cost for each  
15        drug and the source used to determine the maximum allowable cost, which  
16        shall not be dependent upon individual beneficiary identification or benefit  
17        stage.

18            (2) Update the maximum allowable cost at least once every seven  
19        calendar days. In order to be subject to maximum allowable cost, a drug must  
20        be widely available for purchase by all pharmacies in the State, without

1 limitations, from national or regional wholesalers and must not be obsolete or  
2 temporarily unavailable.

3 (3) Establish or maintain a reasonable administrative appeals process to  
4 allow a dispensing pharmacy provider to contest a listed maximum allowable  
5 cost.

6 (4)(A) Respond in writing to any appealing pharmacy provider within  
7 10 calendar days after receipt of an appeal, provided that, except as provided in  
8 subdivision (B) of this subdivision (4), a dispensing pharmacy provider shall  
9 file any appeal within 10 calendar days from the date its claim for  
10 reimbursement is adjudicated.

11 (B) A pharmacy benefit manager shall allow a dispensing pharmacy  
12 provider to appeal after the 10-calendar-day appeal period set forth in  
13 subdivision (A) of this subdivision (4) if the prescription claim is subject to an  
14 audit initiated by the pharmacy benefit manager or its auditing agent.

15 (5) For a denied appeal, provide the reason for the denial and identify  
16 the national drug code and a Vermont-licensed wholesaler of an equivalent  
17 drug product that may be purchased by contracted pharmacies at or below the  
18 maximum allowable cost.

19 (6) For an appeal in which the appealing pharmacy is successful:

20 (A) make the change in the maximum allowable cost within 30  
21 business days after the redetermination; and

1           (B) allow the appealing pharmacy or pharmacist to reverse and rebill  
2           the claim in question.

3           ~~(d)~~(g) A pharmacy benefit manager shall not:

4           (1) require a claim for a drug to include a modifier or supplemental  
5           transmission, or both, to indicate that the drug is a 340B drug unless the claim  
6           is for payment, directly or indirectly, by Medicaid; or

7           (2) restrict access to a pharmacy network or adjust reimbursement rates  
8           based on a pharmacy’s participation in a 340B contract pharmacy arrangement.

9           (h)(1) A pharmacy benefit manager or other third party that reimburses a  
10          340B covered entity for drugs that are subject to an agreement under 42 U.S.C.  
11          § 256b through the 340B drug pricing program shall not reimburse the 340B  
12          covered entity for pharmacy-dispensed drugs at a rate lower than that paid for  
13          the same drug to pharmacies that are not 340B covered entities, and the  
14          pharmacy benefit manager shall not assess any fee, charge-back, or other  
15          adjustment on the 340B covered entity on the basis that the covered entity  
16          participates in the 340B program as set forth in 42 U.S.C. § 256b.

17          (2) With respect to a patient who is eligible to receive drugs that are  
18          subject to an agreement under 42 U.S.C. § 256b through the 340B drug pricing  
19          program, a pharmacy benefit manager or other third party that makes payment  
20          for the drugs shall not discriminate against a 340B covered entity in a manner

1 that prevents or interferes with the patient’s choice to receive the drugs from  
2 the 340B covered entity.

3 (i) A pharmacy benefit manager shall not reimburse a pharmacy or  
4 pharmacist in this State an amount less than the amount the pharmacy benefit  
5 manager reimburses a pharmacy benefit manager affiliate for providing the  
6 same pharmacist services.

7 (j) A pharmacy benefit manager shall not restrict, limit, or impose  
8 requirements on a licensed pharmacy in excess of those set forth by the  
9 Vermont Board of Pharmacy or by other State or federal law, nor shall it  
10 withhold reimbursement for services on the basis of noncompliance with  
11 participation requirements.

12 (k) A pharmacy benefit manager shall provide notice to all participating  
13 pharmacies prior to changing its drug formulary.

14 Sec. 3. 18 V.S.A. § 3802 is amended to read:

15 § 3802. PHARMACY RIGHTS DURING AN AUDIT

16 Notwithstanding any provision of law to the contrary, whenever a health  
17 insurer, a third-party payer, or an entity representing a responsible party  
18 conducts an audit of the records of a pharmacy, the pharmacy shall have a right  
19 to all of the following:

20 \* \* \*

1           (2) If an audit is to be conducted on-site at a pharmacy, the entity  
2 conducting the audit:

3           (A) shall give the pharmacy at least 14 days' advance written notice  
4 of the audit and the specific prescriptions to be included in the audit; ~~and~~

5           (B) ~~may~~ shall not audit a pharmacy on Mondays or on weeks  
6 containing a federal holiday, unless the pharmacy agrees to alternative timing  
7 for the audit; and

8           ~~(3) Not to have an entity~~

9           (C) shall not audit claims that:

10           ~~(A)(i)~~ were submitted to the pharmacy benefit manager more than  
11 18 months prior to the date of the audit, unless:

12           ~~(i)(I)~~ required by federal law; or

13           ~~(ii)(II)~~ the originating prescription was dated within the 24-  
14 month period preceding the date of the audit; or

15           ~~(B)(ii)~~ exceed 200 selected prescription claims.

16           (3) If any audit is to be conducted remotely, the entity conducting the  
17 audit:

18           (A) shall give the pharmacy at least seven business days following  
19 the pharmacy's confirmation of receipt of the notice of the audit to respond to  
20 the audit; and

21           (B) shall not audit claims that:

1                    (i) were submitted to the pharmacy benefit manager more than  
2                    three months prior to the date of the audit or on a date earlier than that for  
3                    which the pharmacy could electronically retransmit a corrected claim; or  
4                    (ii) exceed five selected prescription claims.

5                    \* \* \*

6                    (19) To have the preliminary audit report delivered to the pharmacy  
7                    within ~~60~~ 30 days following the ~~conclusion of the audit~~ pharmacy's  
8                    preliminary response.

9                    \* \* \*

10                    (21) To have a final audit report delivered to the pharmacy within ~~120~~  
11                    30 days after the end of the appeals period, as required by section 3803 of this  
12                    title.

13                    \* \* \*

14                    (24) To have all payment data related to audited claims, including:  
15                    (A) payment amount;  
16                    (B) any direct and indirect remuneration (DIR) or generic effective  
17                    rate (GER) fees assessed or other financial offsets;  
18                    (C) date of electronic payment or check date and number;  
19                    (D) the specific contracted reimbursement basis for each claim,  
20                    including its basis, such as maximum allowable cost (MAC), wholesale



1 acquisition cost (WAC), average wholesale price (AWP), or average  
2 manufacturer price (AMP); and

3 (E) the respective values used to calculate each claim payment.

4 Sec. 4. 8 V.S.A. § 4089j is amended to read:

5 § 4089j. RETAIL PHARMACIES; FILLING OF PRESCRIPTIONS

6 (a) As used in this section:

7 \* \* \*

8 (4) “Pharmacy benefit manager affiliate” means a pharmacy or  
9 pharmacist that, directly or indirectly, through one or more intermediaries, is  
10 owned or controlled by, or is under common ownership or control with, a  
11 pharmacy benefit manager.

12 (5) “Drug” or “prescription drug” has the same meaning as “prescription  
13 drug” in 26 V.S.A. § 2022 and includes:

14 (A) biological products, as defined in 18 V.S.A. § 4601;

15 (B) medications used to treat complex, chronic conditions, including  
16 medications that require administration, infusion, or injection by a health care  
17 professional;

18 (C) medications for which the manufacturer or the U.S. Food and  
19 Drug Administration requires exclusive, restricted, or limited distribution; and

20 (D) medications with specialized handling, storage, or inventory  
21 reporting requirements.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20

\* \* \*

(b) A health insurer ~~and~~ or pharmacy benefit manager doing business in Vermont shall permit a retail pharmacist licensed under 26 V.S.A. chapter 36 to fill prescriptions for all prescription drugs in the same manner and at the same level of reimbursement as they are filled by ~~mail-order pharmacies~~ any other pharmacist or pharmacy, including a mail-order pharmacy or a pharmacy benefit manager affiliate, with respect to the quantity of drugs or days' supply of drugs dispensed under each prescription.

(c) Notwithstanding any provision of a health insurance plan to the contrary, if a health insurance plan provides for payment or reimbursement that is within the lawful scope of practice of a pharmacist, the insurer may provide payment or reimbursement for the service when the service is provided by a pharmacist.

(d)(1) A health insurer or pharmacy benefit manager shall permit a beneficiary of a plan offered by the health insurer to fill a prescription for a drug at the in-network pharmacy of the beneficiary's choice and, except with respect to pharmacies owned or operated, or both, by a health care facility, as defined in 18 V.S.A. § 9432, shall not impose differential cost-sharing requirements based on the choice of pharmacy or otherwise promote the use of one pharmacy over another.

1           (2) A health insurer or pharmacy benefit manager shall permit a  
2           participating network pharmacy to perform all pharmacy services within the  
3           lawful scope of the profession of pharmacy as set forth in 26 V.S.A.  
4           chapter 36.

5           (3) A health insurer or pharmacy benefit manager shall not do any of the  
6           following:

7                   (A) Require a covered individual, as a condition of payment or  
8                   reimbursement, to purchase pharmacist services, including prescription drugs,  
9                   exclusively through a mail-order pharmacy or a pharmacy benefit manager  
10                  affiliate.

11                  (B) Offer or implement plan designs that require a covered individual  
12                  to use a mail-order pharmacy or a pharmacy benefit manager affiliate.

13                  (C) Order a covered individual, orally or in writing, including  
14                  through online messaging, to use a mail-order pharmacy or a pharmacy benefit  
15                  manager affiliate.

16                  (D) Establish network requirements that are more restrictive than or  
17                  inconsistent with State or federal law, rules adopted by the Board of Pharmacy,  
18                  or guidance provided by the Board of Pharmacy or by drug manufacturers that  
19                  operate to limit or prohibit a pharmacy or pharmacist from dispensing or  
20                  prescribing drugs.

1           (E) Offer or implement plan designs that increase plan or patient  
2           costs if the covered individual chooses not to use a mail-order pharmacy or a  
3           pharmacy benefit manager affiliate. The prohibition in this subdivision (E)  
4           includes requiring a covered individual to pay the full cost for a prescription  
5           drug when the covered individual chooses not to use a mail-order pharmacy or  
6           a pharmacy benefit manager affiliate.

7           (4) The provisions of this subsection shall not apply to Medicaid.

8           Sec. 4a. 8 V.S.A. § 4089k is added to read:

9           § 4089k. PRESCRIPTION DRUGS DISPENSED BY HEALTH INSURER-

10           DESIGNATED PHARMACIES FOR ADMINISTRATION TO

11           PATIENTS IN A HEALTH CARE SETTING

12           (a) As used in this section:

13           (1) “Health care professional” means an individual licensed to practice  
14           medicine under 26 V.S.A. chapter 23 or 33, an individual licensed as a  
15           naturopathic physician pursuant to 26 V.S.A. chapter 81, an individual licensed  
16           as a physician assistant under 26 V.S.A. chapter 31, or an individual licensed  
17           as an advanced practice registered nurse under 26 V.S.A. chapter 28.

18           (2) “Health care setting” means a health care professional’s office or a  
19           hospital or clinic at which a health care professional practices.

20           (3) “Health insurer” has the same meaning as in 18 V.S.A. § 9402.

1       (b)(1) A health insurer shall not, by contract, written policy, or written  
2       procedure, require that a pharmacy designated by the health insurer dispense a  
3       medication directly to a patient with the expectation or intention that the  
4       patient will transport the medication to a health care setting for administration  
5       by a health care professional.

6       (2)(A) A health insurer may enter into an agreement with a health care  
7       professional under which a pharmacy designated by the health insurer  
8       dispenses one or more medications directly to a specific patient for the patient  
9       to transport to a health care setting for the health care professional to  
10       administer to the patient.

11       (B) A health insurer that enters into an agreement pursuant to this  
12       subdivision (2) shall attest to the Department of Financial Regulation, in a  
13       form and manner determined by the Department, that:

14               (i) the health insurer provides an expedited, patient-specific  
15       exception process for cases in which the health care professional certifies that  
16       it is unsafe for an individual patient to receive medication directly from the  
17       health insurer-designated pharmacy;

18               (ii) the health insurer-designated pharmacy provides for same-day  
19       delivery of medications to patients;

20               (iii) the health insurer-designated pharmacy is accredited by a  
21       national pharmacy accreditation organization;

1                   (iv) the health insurer-designated pharmacy has the ability to  
2                   deliver medications to the patient’s home in a clinically appropriate dosage and  
3                   in a ready-to-administer form;

4                   (v) the health insurer-designated pharmacy utilizes cold chain  
5                   logistics or other means to ensure that each medication remains at the  
6                   appropriate temperature through all stages of supply, storage, and delivery;

7                   (vi) the health insurer-designated pharmacy provides a  
8                   medication’s pedigree to certify to the health care professional that the  
9                   medication was handled appropriately throughout the supply chain;

10                  (vii) the health insurer-designated pharmacy demonstrates  
11                  expertise and reliability in risk evaluation and mitigation strategy that comply  
12                  with U.S. Food and Drug Administration reporting requirements; and

13                  (viii) the health insurer or the health insurer-designated pharmacy,  
14                  or both, make access to a pharmacist or nurse available 24 hours per day, seven  
15                  days per week.

16                  (c)(1) A health insurer shall not, by contract, written policy, or written  
17                  procedure, require that a pharmacy designated by the health insurer dispense a  
18                  medication directly to a health care setting for a health care professional to  
19                  administer to a patient.

20                  (2)(A) A health insurer may enter into an agreement with a health care  
21                  professional under which a pharmacy designated by the health insurer

1 dispenses one or more medications for a specific patient directly to a health  
2 care setting for the health care professional to administer to the patient.

3 (B) A health insurer that enters into an agreement pursuant to this  
4 subdivision (2) shall attest to the Department of Financial Regulation, in a  
5 form and manner determined by the Department, that:

6 (i) the health insurer provides an expedited, patient-specific  
7 exception process for cases in which a health care professional certifies that it  
8 is unsafe for an individual patient’s medication to come directly from the  
9 health insurer-designated pharmacy;

10 (ii) the health insurer-designated pharmacy provides for same-day  
11 delivery of medications from the health insurer-designated pharmacy to the  
12 health care setting;

13 (iii) the health insurer-designated pharmacy is accredited by a  
14 national pharmacy accreditation organization;

15 (iv) the health insurer-designated pharmacy has the ability to  
16 deliver medications to the health care setting in a clinically appropriate dosage  
17 and in a ready-to-administer form;

18 (v) the health insurer-designated pharmacy utilizes cold chain  
19 logistics or other means to ensure that each medication remains at the  
20 appropriate temperature through all stages of supply, storage, and delivery;

1                   (vi) the health insurer-designated pharmacy provides a  
2                   medication’s pedigree to certify to the health care professional that the  
3                   medication was handled appropriately throughout the supply chain;

4                   (vii) the health insurer-designated pharmacy demonstrates  
5                   expertise and reliability in risk evaluation and mitigation strategy that comply  
6                   with U.S. Food and Drug Administration reporting requirements;

7                   (viii) the health insurer or the health insurer-designated pharmacy,  
8                   or both, make access to a pharmacist available 24 hours per day, seven days  
9                   per week; and

10                  (ix) the health insurer offers payment policies that reimburse for  
11                  office-administered medications at the same rates, regardless of whether the  
12                  medications were obtained from a pharmacy designated by the insurer or by  
13                  the health care professional or health care setting, which payment shall include  
14                  the costs for the health care professional or health care setting to intake, store,  
15                  compound, and dispose of the medications.

16                  (d) A health insurer shall not, by contract, written policy, or written  
17                  procedure, require:

18                   (1) sterile compounding by a health care professional in a health care  
19                   setting without providing reimbursement to the health care professional for that  
20                   service; or



1           (2) a medication with a patient-specific dosage requirement to be based  
2           on lab or test results on the day of the patient visit to be distributed from a  
3           health insurer-designated pharmacy to a health care setting for administration.

4           (e) A health insurer may offer coverage for, but shall not require the use of:

5           (1) a home-infusion pharmacy to dispense sterile intravenous drugs  
6           prescribed by a treating health care professional to a patient in the patient’s  
7           home; or

8           (2) an infusion site other than the treating health care professional’s  
9           office or a hospital or clinic at which the health care professional practices.

10          Sec. 4b. 18 V.S.A. chapter 91, subchapter 5 is added to read:

11                               Subchapter 5. Preferential Drug Pricing

12                               § 4671. INTERFERENCE WITH PREFERENTIAL DRUG PRICING

13                                       PROGRAMS PROHIBITED

14           (a) A hospital or health clinic in this State that is entitled to preferential  
15           pricing on outpatient prescription drugs under federal or State law or by  
16           contract may purchase such drugs at preferential prices and arrange for their  
17           shipment to a duly licensed pharmacy under contract with the hospital or clinic  
18           for purposes of dispensing the drugs on the hospital’s or clinic’s behalf.

19           (b) No manufacturer or supplier of outpatient prescription drugs for which  
20           a hospital or health clinic in this State is entitled to preferential pricing under  
21           federal or State law or by contract shall deny shipment of such drugs to the

1 hospital's or clinic's contract pharmacy or place conditions or restrictions on  
2 the sale of the drugs.

3 Sec. 5. DEPARTMENT OF FINANCIAL REGULATION; PHARMACY  
4 BENEFIT MANAGEMENT; REPORT

5 (a) The Department of Financial Regulation, in consultation with interested  
6 stakeholders, shall consider:

7 (1) whether pharmacy benefit managers should be required to be  
8 licensed to operate in this State;

9 (2) whether pharmacy benefit managers should be prohibited from  
10 conducting or participating in spread pricing;

11 (3) the cost impacts of pharmacy benefit manager licensure and related  
12 regulatory measures in other states that have enacted such legislation;

13 (4) in collaboration with the Board of Pharmacy, whether any  
14 amendments to the Board's rules are needed to reflect necessary distinctions or  
15 appropriate limitations on pharmacist scope of practice;

16 (5) whether there should be a minimum dispensing fee that pharmacy  
17 benefit managers and health insurers must pay to pharmacies and pharmacists  
18 for dispensing prescription drugs;

19 (6) how a pharmacy should be reimbursed for a claim if a pharmacy  
20 benefit manager denies a pharmacy's appeal in whole or in part, including  
21 whether the pharmacy should be allowed to submit a claim to the health insurer

1 for the balance between the pharmacy benefit manager’s reimbursement and  
2 the pharmacy’s reasonable acquisition cost plus a dispensing fee;

3 (7) whether there is a problem in Vermont of pharmacies soliciting  
4 health insurance plan beneficiaries directly to market the pharmacy’s services  
5 and, if so, how best to address the problem; and

6 (8) other issues relating to pharmacy benefit management and its effects  
7 on Vermonters, on pharmacies and pharmacists, and on health insurance in this  
8 State.

9 (b) On or before January 15, 2023, the Department of Financial Regulation  
10 shall provide its findings and recommendations regarding the issues described  
11 in subsection (a) of this section to the House Committee on Health Care and  
12 the Senate Committees on Health and Welfare and on Finance.

13 Sec. 6. APPLICABILITY

14 (a) The provisions of Sec. 2 of this act (18 V.S.A. chapter 221, subchapter  
15 9, pharmacy benefit managers) shall apply to a contract or health plan issued,  
16 offered, renewed, recredentialed, amended, or extended on or after the  
17 effective date of this act, including any health insurer that performs claims  
18 processing or other prescription drug or device services through a third party.

19 (b) A person doing business in this State as a pharmacy benefit manager on  
20 or before the effective date of this act shall have six months following the

1 effective date of this act to come into compliance with the provisions of Sec. 2  
2 of this act (18 V.S.A. chapter 221, subchapter 9, pharmacy benefit managers).

3 Sec. 7. 2021 Acts and Resolves No. 74, Sec. E.227.2 is amended to read:

4 Sec. E.227.2 REPEAL

5 18 V.S.A. § 9473~~(d)~~(g) (pharmacy benefit managers; 340B entities) is  
6 repealed on ~~January 1, 2023~~ April 1, 2024.

7 Sec. 8. EFFECTIVE DATES

8 This act shall take effect on July 1, 2022, except that Sec. 4, 8 V.S.A.  
9 § 4089j, shall take effect on January 1, 2023.

10

11

12

13

14

15

16

17 (Committee vote: \_\_\_\_\_)

18

19

20

\_\_\_\_\_

Senator \_\_\_\_\_

FOR THE COMMITTEE